Description

N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.–Applications-Cancer-Kinase/protease-Formula-C60H81ClFN11O15-Citation–References–CASNumber–MolecularWeight-1250.80-Compound Purity–SMILES-ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCNC(OCC4=CC=C(NC([C@H](CCCCN)NC([C@@H](NC(CCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])=O)CC5=CC=CC=C5)=O)=O)C=C4)=O)=C1)F-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Drug-Linker Conjugates for ADC-Isoform-Traditional Cytotoxic Agents-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related